Link to this page
National Cancer Institute Thesaurus
| Preferred Name | Bosutinib | |
| Synonyms |
4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile 4-Anilino-3-quinolinecarbonitrile 4-Anilinobenzo(g)quinoline-3-carbonitrile BOSUTINIB Bosutinib SKI 606 SKI-606 |
|
| Definitions |
A synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Unlike imatinib, bosutinib inhibits the autophosphorylation of both Abl and Src kinases, resulting in inhibition of cell growth and apoptosis. Because of the dual mechanism of action, this agent may have activity in resistant CML disease, other myeloid malignancies and solid tumors. Abl kinase is upregulated in the presence of the abnormal Bcr-abl fusion protein which is commonly associated with chronic myeloid leukemia (CML). Overexpression of specific Src kinases is also associated with the imatinib-resistant CML phenotype. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C60809 |
|
| CAS_Registry |
380843-75-4
|
|
| CHEBI_ID |
CHEBI:39112
|
|
| Chemical_Formula |
C26H29Cl2N5O3
|
|
| code |
C60809
|
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
| Contributing_Source |
CTRP FDA GDC HemOnc
|
|
| DEFINITION |
A synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Unlike imatinib, bosutinib inhibits the autophosphorylation of both Abl and Src kinases, resulting in inhibition of cell growth and apoptosis. Because of the dual mechanism of action, this agent may have activity in resistant CML disease, other myeloid malignancies and solid tumors. Abl kinase is upregulated in the presence of the abnormal Bcr-abl fusion protein which is commonly associated with chronic myeloid leukemia (CML). Overexpression of specific Src kinases is also associated with the imatinib-resistant CML phenotype.
|
|
| Display_Name |
Bosutinib
|
|
| FDA_UNII_Code |
5018V4AEZ0
|
|
| FULL_SYN |
4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile 4-Anilino-3-quinolinecarbonitrile 4-Anilinobenzo(g)quinoline-3-carbonitrile BOSUTINIB Bosutinib SKI 606 SKI-606
|
|
| Has_Target | ||
| Is_Value_For_GDC_Property | ||
| label |
Bosutinib
|
|
| Legacy Concept Name |
Bosutinib
|
|
| Maps_To |
Bosutinib
|
|
| NCI_Drug_Dictionary_ID |
467222
|
|
| PDQ_Closed_Trial_Search_ID |
467222
|
|
| PDQ_Open_Trial_Search_ID |
467222
|
|
| Preferred_Name |
Bosutinib
|
|
| prefixIRI |
Thesaurus:C60809
|
|
| Semantic_Type |
Organic Chemical Pharmacologic Substance
|
|
| UMLS_CUI |
C1831731
|
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |